The company that develops functional treatments for specific cardiomyopathies also attracted the resources of EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, and SEEDS Capital
Nuevocor, a Singapore’s developer functional treatments for specific cardiomyopathies that has offices in USA that aims to expand in Europe, said it raised a Series B round of 45 million US Dollars that Italy’s Angelini Ventures and French Kurma Partners led. The company also attracted the resources of its current investors EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, and SEEDS Capital (press release).
In 2021, Nuevocor secured a Series A 24 million round that EVX Ventures e Boehringer Ingelheim Venture Fund (BIVF), EDBI, Xora Innovation, SEEDS Capital, and other investors joined (press release).
Elia Stupka of Angelini Ventures and Amanda Gett-Chaperot of Kurma Partners joined Nuevocor board of directors.
The company will invest the raised resources in the first phase 1/2 clinical trial to appraise the safety and efficacy of the lead drug candidate, NVC-001, targeted at dilated cardiomyopathy associated with LMNA gene mutations (LMNA-DCM). The clinical trial will be open-label, multicentre and single ascending dose.
Yann Chong Tan, MD, the ceo and co-founder of Nuevocor, said: “We are delighted to have achieved this significant funding milestone and to be able to build global partnerships with a group of experienced life science investors. Their support will enable Nuevocor to continue its strong momentum and bring NVC-001 to the clinic. There is a huge unmet need for people with cardiomyopathies and, with the help of our effective mechanobiology platform, we continue to build our pipeline of targeted, breakthrough drugs for these patients”.
Gett-Chaperot, a partner of Kurma, added: “Nuevocor is providing new hope to a significant population of patients with cardiovascular disease who currently lack treatment options by acting directly on the underlying causes of the disease. The burden of cardiomyopathies is significant and Kurma is excited to join Nuevocor, investing from the new Biofund IV to create significant value through the treatment of these serious diseases.”
Stupka, a managing director of Angelini Ventures, said: “Our investment in Nuevocor represents a strategic expansion in the cardiovascular field, addressing an important unmet medical need with a truly innovative approach. What makes Nuevocor’s mechanistic gene therapy platform particularly attractive is its ability to target the pathways underlying genetic dilated cardiomyopathy, rather than simply replacing mutated genes. This approach has the potential to help thousands of patients who currently face the prospect of multiple heart transplants during their lifetime. By intervening at the mechanobiological level to block harmful signalling pathways, Nuevocor’s technology offers hope for a unique treatment that could dramatically improve patients’ quality of life while significantly reducing the enormous burden on healthcare systems. As Nuevocor advances towards clinical trials, we are proud to join its board of directors and support its mission to transform treatment paradigms for this disease.”
Nuevocor is Angelini Ventures’ first Asian investment and also in the field of in a new therapeutic area for cardiovascular health. In January 2025, the Italian fund joined the Belgium’s AgeTech Series B round of 35 million euros (see here a previous post by BeBeez), Danish Neumirna Therapeutics’ Series A round of 20 million (see here a previous post by BeBeez) and the 10 million Series A round of 10 million that German Vantis launched in March (see here a previous post by BeBeez).
Angelini Ventures is born in 2022 and set a 300 million investment target (see here a previous post by BeBeez). The fund already allocated 100 million in 19 companies such as Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience, Freya Biosciences, Neumirna Therapeutics, Nobi, Vantis, and others.
BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Angelini Ventures and its Italian portfolio companies. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager
